Women with DCIS at higher risk of death from breast cancer
According to new research, women with ductal carcinoma in situ (DCIS) are more than three times as likely to suffer from breast cancer mortality than women in the general population.
Researchers from the University of Toronto conducted a study, published in JAMA Network Open, that investigated the actual risk of death associated with DCIS in women with a DCIS diagnosis between 1995 and 2014.
“In the population studied, the risk of dying of breast cancer…suggests that our current treatment focus on preventing invasive recurrence is insufficient to eliminate all deaths from breast cancer after DCIS,” said the team led by Vasily Giannakeas, MPH, a doctoral candidate at the University of Toronto and Women’s College Research Institute.
Read more about the findings and their implications on Diagnostic Imaging.
Exogenous hormones and patients at increased risk for breast cancer
October 17th 2023This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.
Read More
Hormone replacement therapy does not increase breast cancer recurrence, mortality in survivors
July 20th 2022An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.
Read More
